NCT06334562 The Clinical Effect of Sugammadex Sodium (Domestic) for Antagonizing Neuromuscular Blockade After Thoracic Surgery
| NCT ID | NCT06334562 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
| Condition | Neuromuscular Blockade |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2025-12-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study aims to compare the use of sugammadex (domestic) and neostigmine for antagonism after thoracic surgery, and observe the effect of sugammadex (domestic) on neuromuscular blockade antagonism after thoracic surgery, in order to provide a basis for optimizing the use of muscle relaxants and their antagonists during anesthesia.
Eligibility Criteria
Inclusion Criteria: 1. Patients who undergo elective lung surgery under general anesthesia and require endotracheal intubation; 2. Age\>18 years old, gender not limited; 3. American Society of Anesthesiologists ASA Level I-III; 4. Use rocuronium bromide for neuromuscular blockade; 5. The patient voluntarily participated in the trial. Exclusion Criteria: 1. The patient explicitly refused to participate in this trial; 2. Family history of malignant hyperthermia, patients with allergies to sodium sulbactam, neostigmine ingredients and their excipients, and patients with allergies to drugs used during general anesthesia; 3. Patients with tracheal malformations or suspected difficult airways, coagulation dysfunction, severe liver and kidney dysfunction, and severe lung disease; 4. Patients who are not extubated and sent to the ward or ICU after surgery; 5. The researchers believe that patients with any other unfavorable factors to participate in this trial.